Repligen's Q4 Slightly Tops Expectations

Repligen (NASDAQ:RGEN), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimate of $0.41, but fell year over year. Revenue of $168 million, meanwhile, came in modestly above expectations of $167 million and up from $167 million in the prior-year period. However, its GAAP gross margin declined significantly to 23.2% from 47.1% a year prior.Source: Analyst estimates for the quarter provided by FactSet.Repligen is a leader in the development and production of innovative technologies used in the manufacturing of biological drugs, including therapeutic antibodies, vaccines, and cell and gene therapies. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool